Risk of Hepatic and Gastrointestinal (GI) Events in Patients Newly Diagnosed with Neuroendocrine Tumors (NET)

#260

Introduction: NET derives from peptide- and hormone-producing cells scattered throughout the body. In excess, these can lead to many clinical manifestations, including GI events (ex. enteritis, and liver disease).

Aim(s): To estimate the incremental risk of hepatic/GI events in the first three years post-diagnosis, comparing NET v. general non-cancer population.

Materials and methods: A retrospective matched-control cohort study was conducted using claims databases. New NET patients were indexed from 2001 to 2007 (ICD-9 CM: 157.4/209.xx/258.01/259.2). Non-cancer patients were matched 2:1 to NET patients on age, gender, and other characteristics. Hepatic/GI events were compared using multivariate Cox and logistic models.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Hess G, Liu Z, Chen C, Yao J, Phan A,

Keywords: neuroendocrine tumors, clinical characteristics, hepatic/gastrointestinal events,